No, President Trump, biopharma does not want you to deregulate drug development
Nobody wants radical changes at the FDA, except perhaps President Trump and a few close associates.
We’ve been tracking the industry’s clear reluctance to discard the FDA gold standard in drug development. In our most recent survey yesterday, a plurality of biotech execs voted against significant changes at the agency, saying that reforms over the past few years has already sped up the process. And many of the execs that would like to see continued change were clearly more interested in specifically tailored upgrades, not a wholesale overhaul.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters